Acute graft-versus-host disease
Transplant complication · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Donor immune cells attacking recipient tissues after allogeneic stem-cell transplant, classically affecting skin (rash), gut (diarrhoea) and liver (cholestasis). Usually within the first weeks to 100 days.
Red flags
- High-volume/bloody diarrhoea and ileus
- Rapidly rising bilirubin
- Extensive/bullous skin involvement
- Concurrent infection/sepsis
Assessment
Differential diagnosis
- Drug reaction/DRESS
- Infectious enteritis (CMV, C. difficile)
- Viral hepatitis / drug hepatotoxicity
- Engraftment syndrome
- Sepsis
Investigations
- Clinical staging of skin, gut and liver involvement
- LFTs, U&E, FBC
- Stool studies (exclude infection, especially CMV and C. difficile)
- Skin/gut biopsy to confirm; CMV monitoring
Management
- Confirm diagnosis and exclude infection mimics (biopsy where possible)
- Continue calcineurin inhibitor prophylaxis and optimise levels
- Start systemic corticosteroids as first-line treatment for significant (grade >=II) disease
- Supportive care - fluids, nutrition, skin care, gut rest
- Involve the transplant team; escalate to second-line immunosuppression (e.g. ruxolitinib) for steroid-refractory disease
Drugs & doses
Systemic corticosteroids (first line)
Calcineurin inhibitor (ciclosporin/tacrolimus) continuation
Ruxolitinib for steroid-refractory acute GVHD
Topical steroids for limited skin disease; supportive/antimicrobial cover
Disposition
Admit under/with the transplant haematology team; ICU/HDU for severe multi-organ disease.
Complications & pitfalls
- Severe fluid/electrolyte loss and malnutrition
- Life-threatening infection from immunosuppression
- Progression to chronic GVHD
- Death
Exam pearls
- Exclude infection (CMV, C. difficile) which mimics and coexists with gut GVHD.
- Steroid-refractory GVHD carries a poor prognosis - escalate promptly with the transplant team (ruxolitinib is a recognised option).
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.